Parker Geoffrey M. 4

4 · Allogene Therapeutics, Inc. · Filed Feb 4, 2026

AI-generated summary of this filing

Updated Feb 4, 2026

Allogene (ALLO) CFO Geoffrey Parker Receives RSUs, Sells 24,001 Shares

What Happened

Geoffrey M. Parker, Chief Financial Officer of Allogene Therapeutics (ALLO), received stock awards and completed a sell-to-cover share sale on Feb 2, 2026. He was granted a total of 691,552 restricted stock units (RSUs) in two awards (539,072 and 152,480 RSUs) reported at $0.00 (derivative awards). On the same day he sold 24,001 shares in open-market transactions at a weighted average price of $1.76 for proceeds of $42,242. The sale was to cover tax withholding and not a discretionary open-market trade.

Key Details

Transaction date: Feb 2, 2026; Form 4 filed Feb 4, 2026 (timely — within the two-business-day window).
Sale: 24,001 shares sold, weighted average price $1.76 (range $1.71–$1.83); total reported proceeds $42,242. (Footnote: multiple trades at different prices; detailed breakdown available on request.)
Awards: 539,072 RSUs and 152,480 RSUs (total 691,552 RSUs) reported as derivative awards at $0.00; RSUs convert to one share each upon vesting.
Shares owned after transaction: not specified in this filing.
Notable footnotes:
- F1: The sale was a mandated "sell-to-cover" to satisfy tax withholding — not a discretionary sale.
- F2: Reported sale price is a weighted average; individual trades ranged $1.71–$1.83.
- F3: Describes an option vesting schedule (25% on Feb 2, 2027, then monthly over 36 months) — pertains to stock option vesting language included in the filing materials.
- F4: Confirms the awards are RSUs that vest in four equal annual installments beginning Feb 2, 2026.

Context

The RSU grants are compensation-based awards that vest over time (per F4); they are not open-market purchases and are commonly used to align executive incentives with shareholders. The sale was a routine sell-to-cover for tax withholding, which is a common administrative transaction and does not by itself indicate a change in the insider’s view of the company.

Form 4

Period: 2026-02-02

CHIEF FINANCIAL OFFICER

Transactions

Sale
Common Stock
[F1][F2]
2026-02-02$1.76/sh−24,001$42,242→ 1,252,795 total
Award
Stock Option (Right to buy)
[F3]
2026-02-02+539,072→ 539,072 total
Exercise: $1.87Exp: 2036-02-02→ Common Stock (539,072 underlying)
Award
Restricted Stock Unit
[F4]
2026-02-02+152,480→ 152,480 total
→ Common Stock (152,480 underlying)

Footnotes (4)

[F1]Represents the number of shares sold by the reporting person to cover tax withholding obligations in connection with the vesting of restricted stock units. This sale is mandated by the Issuer's election under its equity incentive plan to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person.
[F2]The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions ranging from $1.71 to $1.83, inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.
[F3]25% of the shares subject to the stock option shall vest on February 2, 2027, and the remaining shares shall vest in 36 equal monthly installments thereafter.
[F4]Represents an award of Restricted Stock Units (RSUs). Each RSU represents a contingent right to receive one share of the Companys Common Stock. The RSUs will vest in 4 successive equal annual installments over the four-year period measured from February 2, 2026, subject to continued service through the vesting date.

Signature

/s/Earl Douglas, Attorney-in-Fact|2026-02-04

1 file